Our top pick for
Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cancer therapies developer Theseus Pharmaceuticals wrapped its initial public offering Thursday, selling 10 million shares at $16 each, the high end of its proposed range. The stock will debut on the Nasdaq later today under the ticker symbol THRX, but shares are available for limit orders at Robinhood and other platforms.
|Latest market close||$5.70|
|52-week range||$4.86 - $24.54|
|50-day moving average||$7.24|
|200-day moving average||$11.34|
|Wall St. target price||$21.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.76|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-24)||-5.32%|
|1 month (2022-06-03)||-5.16%|
|3 months (2022-04-04)||-55.98%|
|6 months (2022-01-04)||-48.23%|
|1 year (2021-06-30)||N/A|
|2 years (2020-06-30)||N/A|
|3 years (2019-06-30)||N/A|
|5 years (2017-06-30)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-11.95%|
|Return on equity TTM||-27.22%|
|Market capitalisation||$201.3 million|
TTM: trailing 12 months
We're not expecting Theseus Pharmaceuticals to pay a dividend over the next 12 months.
Theseus Pharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.